MediPharm Labs Corp. LABS MEDIF said Tuesday it has entered into a private label sales agreement for exports to Europe with ADREXpharma GmbH.
The company will provide ADREXpharma with cannabis concentrate derivative products such as CBD and THC oil for sale and distribution under the ADREXpharma brand in Germany, MediPharm Labs said.
ADREXpharma is a licensed distributor of medical cannabis and controlled drugs that can supply around 20,000 pharmacies in Germany, the company said.
“Germany is one of the largest and fastest growing medical cannabis markets in the world and represents MediPharm Labs’ second major international milestone as we prepare to export our private label cannabis concentrates into Germany,” MediPharm CEO Pat McCutcheon said in a statement.
“We are excited to be partnering with ADREXpharma, leveraging their deep expertise and local distribution to bring high quality, purity assured cannabis derivative products into the German market and expand our international exports.”
Click here for more information about the upcoming Benzinga Cannabis Capital Conference Oct. 22-23 in Chicago.
MediPharm shares were down 2.49% at $3.52 at the time of publication.
Don’t miss out on the top cannabis stories of the day. Click here to sign up for our daily insider newsletter.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!
